| scholarly article | Q13442814 |
| P50 | author | Helen M. Arthur | Q39407032 |
| Jonas Fuxe | Q54250889 | ||
| Oriol Casanovas | Q57157744 | ||
| Jill R Johnson | Q57325700 | ||
| Ross Cordiner | Q59123253 | ||
| Kristian Pietras | Q66213999 | ||
| P2093 | author name string | Peter ten Dijke | |
| Marie-José Goumans | |||
| Bengt R Johansson | |||
| Eliane Cortez | |||
| Zhenhua Zhai | |||
| Evangelia Pardali | |||
| Sara I Cunha | |||
| Marcela Franco | |||
| Charlotte Anderberg | |||
| Marta Páez-Ribes | |||
| P2860 | cites work | Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex | Q24294521 |
| Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression | Q24595357 | ||
| Modes of resistance to anti-angiogenic therapy | Q24608005 | ||
| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis | Q28131703 | ||
| Defective angiogenesis in mice lacking endoglin | Q28144833 | ||
| Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide | Q28203483 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| TGFbeta in Cancer | Q28288866 | ||
| PECAM-1 engagement counteracts ICAM-1-induced signaling in brain vascular endothelial cells | Q28584338 | ||
| Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development | Q28585397 | ||
| A murine model of hereditary hemorrhagic telangiectasia | Q28592376 | ||
| Metastasis: from dissemination to organ-specific colonization | Q29614295 | ||
| Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis | Q29614537 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice | Q33263752 | ||
| Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene | Q33679093 | ||
| Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma | Q33730122 | ||
| Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment | Q34024081 | ||
| ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth | Q34096297 | ||
| Sunitinib malate for the treatment of pancreatic neuroendocrine tumors | Q34163515 | ||
| ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary | Q34248487 | ||
| Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
| Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis | Q34586319 | ||
| Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents | Q34603062 | ||
| Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice | Q34787599 | ||
| ALK1 as an emerging target for antiangiogenic therapy of cancer | Q35127963 | ||
| Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth | Q35314203 | ||
| Conversion of vascular endothelial cells into multipotent stem-like cells | Q35532554 | ||
| Contrasting effects of sunitinib within in vivo models of metastasis | Q36394262 | ||
| Extracellular control of TGFbeta signalling in vascular development and disease | Q36951674 | ||
| Endoglin in angiogenesis and vascular diseases | Q37088038 | ||
| Roles of TGFbeta in metastasis | Q37339711 | ||
| Emerging role of bone morphogenetic proteins in angiogenesis | Q37510292 | ||
| The emerging role of TGF-beta superfamily coreceptors in cancer. | Q37553118 | ||
| Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. | Q37578166 | ||
| Signaling by members of the TGF-beta family in vascular morphogenesis and disease | Q37775374 | ||
| Endoglin-Targeted Cancer Therapy | Q37804900 | ||
| TGF-β receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. | Q37880946 | ||
| Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. | Q37898911 | ||
| Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors | Q39345414 | ||
| Vascular endothelial growth factor B controls endothelial fatty acid uptake. | Q39727853 | ||
| Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. | Q39753483 | ||
| Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction | Q40251249 | ||
| Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies | Q40751413 | ||
| Characteristics and possible function of endoglin, a TGF-beta binding protein | Q40785136 | ||
| Endothelial cell membranes contain podocalyxin--the major sialoprotein of visceral glomerular epithelial cells | Q41498433 | ||
| Pericytes limit tumor cell metastasis | Q41916240 | ||
| Lack of primary cilia primes shear-induced endothelial-to-mesenchymal transition. | Q42044394 | ||
| Dextran sulfate sodium leads to chronic colitis and pathological angiogenesis in endoglin heterozygous mice | Q42406987 | ||
| Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes | Q43470250 | ||
| Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome | Q43622808 | ||
| Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality | Q44385668 | ||
| A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. | Q45158856 | ||
| Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF? | Q46299185 | ||
| Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. | Q46541963 | ||
| Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models | Q46659724 | ||
| Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome | Q47808993 | ||
| Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. | Q51618784 | ||
| Endoglin expression in early development is associated with vasculogenesis and angiogenesis. | Q52126579 | ||
| Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. | Q52532578 | ||
| Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. | Q53215929 | ||
| Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. | Q53327257 | ||
| Discovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts | Q58214816 | ||
| A cancer therapy resistant to resistance | Q59070138 | ||
| Pathogenesis of Arteriovenous Malformations in the Absence of Endoglin | Q60205822 | ||
| Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin | Q73738309 | ||
| Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis | Q74462138 | ||
| Sustained enhanced growth of carcinoma EO771 in C57 black mice | Q75781930 | ||
| Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells | Q77392041 | ||
| Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy | Q77555510 | ||
| Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer | Q78035700 | ||
| Reduced angiogenic responses in adult Endoglin heterozygous mice | Q82233917 | ||
| Endothelial progenitor cells give rise to pro-angiogenic smooth muscle-like progeny | Q82554716 | ||
| The role of the TGF-β coreceptor endoglin in cancer | Q82953624 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 563-579 | |
| P577 | publication date | 2013-02-11 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination | |
| P478 | volume | 210 |
| Q36061812 | An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer |
| Q34665377 | AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients |
| Q33770680 | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions |
| Q37672682 | Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling |
| Q41636608 | Cancer cells remodel themselves and vasculature to overcome the endothelial barrier. |
| Q42278077 | Cardiosphere-Derived Cells Require Endoglin for Paracrine-Mediated Angiogenesis |
| Q41900072 | Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling. |
| Q92387633 | Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis |
| Q38164995 | Crossing the endothelial barrier during metastasis |
| Q27334435 | Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets |
| Q54977476 | Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells. |
| Q41889215 | Effects of the combination of TRC105 and bevacizumab on endothelial cell biology |
| Q38180309 | Endoglin for targeted cancer treatment |
| Q40068276 | Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. |
| Q39401943 | Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies. |
| Q89631295 | Endothelial Cells in the Tumor Microenvironment |
| Q35151213 | Endothelial-mesenchymal transition of brain endothelial cells: possible role during metastatic extravasation |
| Q92996743 | Endothelial-to-Mesenchymal Transition (EndoMT): Roles in Tumorigenesis, Metastatic Extravasation and Therapy Resistance |
| Q95936615 | Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage |
| Q47229175 | Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma. |
| Q35158941 | Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105) |
| Q92062302 | Fibroblast growth factor signals regulate transforming growth factor-β-induced endothelial-to-myofibroblast transition of tumor endothelial cells via Elk1 |
| Q39406918 | Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. |
| Q30275793 | Fine-tuning vascular fate during endothelial-mesenchymal transition |
| Q36607541 | Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DD |
| Q51443453 | Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks. |
| Q30278010 | KLF4 is a key determinant in the development and progression of cerebral cavernous malformations |
| Q28508560 | LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. |
| Q91727642 | Loss of Endothelial Endoglin Promotes High-Output Heart Failure Through Peripheral Arteriovenous Shunting Driven by VEGF Signaling |
| Q38712440 | MiR-942 decreased before 20 weeks gestation in women with preeclampsia and was associated with the pathophysiology of preeclampsia in vitro |
| Q33913556 | Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. |
| Q33957962 | Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? |
| Q91259833 | Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness |
| Q91259831 | Opening the vascular gate |
| Q51008382 | Overexpression of protein kinase STK25 in mice exacerbates ectopic lipid accumulation, mitochondrial dysfunction and insulin resistance in skeletal muscle. |
| Q98612770 | Past, Present, and Future of Anticancer Nanomedicine |
| Q39185439 | Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals. |
| Q38293612 | Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. |
| Q35680766 | Prognostic Significance of Microvessel Density Determining by Endoglin in Stage II Rectal Carcinoma: A Retrospective Analysis |
| Q41015734 | Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. |
| Q36825558 | Recurrences in stage II rectal carcinoma after curative resection alone: from the viewpoint of angiogenesis |
| Q60915777 | Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy |
| Q92734444 | Role of soluble endoglin in BMP9 signaling |
| Q26748863 | Safety of targeting tumor endothelial cell antigens |
| Q58703191 | Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia |
| Q37479646 | Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls |
| Q91754855 | Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer |
| Q38256407 | TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets. |
| Q94564513 | TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering |
| Q47988392 | The Rip1Tag2 Transgenic Mouse Model |
| Q39036151 | The role of endoglin in post-ischemic revascularization. |
| Q35251863 | Tumor Endothelial Cells with Distinct Patterns of TGFβ-Driven Endothelial-to-Mesenchymal Transition |
| Q36747249 | VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread |
| Q38780879 | When the endothelium scores an own goal: endothelial cells actively augment metastatic extravasation through endothelial-mesenchymal transition. |
| Q35917632 | miR-342-5p Is a Notch Downstream Molecule and Regulates Multiple Angiogenic Pathways Including Notch, Vascular Endothelial Growth Factor and Transforming Growth Factor β Signaling |
Search more.